Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Clinical Study Of Schizophrenia in Both Men and Women

ClinicalTrials.gov ID: NCT00071747

Public ClinicalTrials.gov record NCT00071747. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Double Blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine Versus Placebo As Add-On Therapy In Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.

Study identification

NCT ID
NCT00071747
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
176 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2003
Primary completion
Not listed
Completion
Dec 31, 2004
Last update posted
Aug 31, 2016

2003 – 2005

United States locations

U.S. sites
32
U.S. states
16
U.S. cities
31
Facility City State ZIP Site status
GSK Investigational Site Little Rock Arkansas 72201 —
GSK Investigational Site Garden Grove California 92845 —
GSK Investigational Site La Mesa California 91942 —
GSK Investigational Site National City California 91950 —
GSK Investigational Site Oceanside California 92056 —
GSK Investigational Site Rosemead California 91770 —
GSK Investigational Site San Diego California 92126 —
GSK Investigational Site Hartford Connecticut 06106 —
GSK Investigational Site Maitland Florida 32751 —
GSK Investigational Site North Miami Florida 33161 —
GSK Investigational Site Granite City Illinois 62040 —
GSK Investigational Site Glen Burnie Maryland 21061 —
GSK Investigational Site Rockville Maryland 20852 —
GSK Investigational Site Boston Massachusetts 02114 —
GSK Investigational Site Reno Nevada 89512 —
GSK Investigational Site Clementon New Jersey 08021 —
GSK Investigational Site Kenilworth New Jersey 07033 —
GSK Investigational Site Orangeburg New York 10962 —
GSK Investigational Site Rochester New York 14620 —
GSK Investigational Site Butner North Carolina 27509 —
GSK Investigational Site Charlotte North Carolina 28211 —
GSK Investigational Site Raleigh North Carolina 27603 —
GSK Investigational Site Raleigh North Carolina 27609 —
GSK Investigational Site Beachwood Ohio 44122 —
GSK Investigational Site Cleveland Ohio 44106 —
GSK Investigational Site Lyndhurst Ohio 44124 —
GSK Investigational Site Norristown Pennsylvania 19401 —
GSK Investigational Site Austin Texas 78756 —
GSK Investigational Site Bellaire Texas 77401 —
GSK Investigational Site DeSoto Texas 75115 —
GSK Investigational Site Midvale Utah 84047 —
GSK Investigational Site Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00071747, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 31, 2016 · Synced Sep 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00071747 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →